Ampligen Approval Status
- FDA approved: No
- Brand name: Ampligen
- Generic name: rintatolimod
- Company: Hemispherx Biopharma, Inc.
- Treatment for: Chronic Fatigue Syndrome
Ampligen (rintatolimod) is an experimental nucleic acid therapeutic in development for the treatment of a variety of chronic diseases and viral disorders.
Development Status and FDA Approval Process for Ampligen
|Feb 9, 2015||Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen Produced 100% Survival Rate in Rodents with 100% Mortality in Placebo|
|Dec 9, 2014||Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen Enlarged by Howard University Research|
|Feb 5, 2013||Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen New Drug Application for Chronic Fatigue Syndrome|
|Dec 27, 2012||FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome|
|Oct 23, 2012||Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012|
|Sep 24, 2012||Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen for Chronic Fatigue Syndrome|
|Aug 14, 2012||FDA Accepts Complete Response Submission Regarding the Ampligen New Drug Application for Chronic Fatigue Syndrome|
|Aug 1, 2012||Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen New Drug Application for Chronic Fatigue Syndrome|
|Mar 7, 2008||Hemispherx Biopharma Reaches Agreement With FDA on Specific Steps
to Achieve Complete NDA on Proposed CFS Treatment Ampligen|
|Jan 9, 2008||Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA|
|Oct 11, 2007||Hemispherx Biopharma Files New Drug Application for Ampligen as
Treatment for Chronic Fatigue Syndrome|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.